Polianta Ltd’s Alnylam Pharmaceuticals ALNY Stock Holding History

Polianta Ltd’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-9,600	Closed	-$1.1M	–	64
2019 Q4	$1.1M	Buy	+9,600	New	+$957K	0.67%	43

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Polianta Ltd's ALNY Position: Q1 2020 in Review

Polianta Ltd sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2020, closing a stake of 9,600 shares — an estimated $1.1M sold.

Polianta Ltd first reported a position in ALNY in Q4 2019 and held it in 1 quarter. The position peaked at $1.1M in Q4 2019. 330 funds tracked by Wall St. Rank hold ALNY as of Q1 2020.

Polianta Ltd reported no remaining Alnylam Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Polianta Ltd sold 9,600 Alnylam Pharmaceuticals shares in Q1 2020, an estimated $1.1M.
Polianta Ltd first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Polianta Ltd's Alnylam Pharmaceuticals position peaked at $1.1M in Q4 2019.
330 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2020.

Based on Polianta Ltd's 13F filing for Q1 2020, filed 7 Apr 2020.